BioSpace News Archive

Updates Full Year 2019 Guidance & Announces Management Changes

BioReference Laboratories, Inc. (“BioReference”) announced today that it is mailing letters to some of its patients whose information may have been included in the American Medical Collection Agency (“AMCA”) security incident previously announced.

MJH Life Sciences will consist of multimedia operations and agency services, Truth Serum Network

Mezzion Pharma Co. Ltd. today announced that top line data from the Phase 3 FUEL trial, which was designed to evaluate the safety and efficacy of udenafil for the treatment of certain adolescents with congenital single ventricle heart disease (SVHD), had positive results for key parameters.

Khiron Life Sciences Corp. reports that the Company has received final approval from the TSX Venture Exchange to close its previously announced acquisition of NettaGrowth International Inc., which owns all of the outstanding shares of a Uruguayan company, Dormul S.A..

The U.S. Food and Drug Administration (FDA) today approved Nubeqa® (darolutamide), an androgen receptor inhibitor (ARi), for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC)

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointment of Mark Avagliano as Chief Business Officer.

On July 30, 2019, a flexible portfolio of small molecule inhibitors targeted for cancer immunotherapy research has made its debut in BOC Sciences, a New York-based chemical vendor that specializes in supply of various bio-chemicals like APIs, metabolites, impurities, ADCs, pharmaceutical excipients, intermediates and more.

AVITA Medical, a global regenerative medicine company, announced that it filed today with the ASX its Appendix 4C - Quarterly Cash Flow Report for the quarter ended 30 June 2019, the fourth quarter of its fiscal 2019.

Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI) enabled patient centric clinical trial matching, announces today its newly developed “Hub” aimed to build strategic partnerships with some of the most prominent Just-In-Time (JIT) vendors and provider clinical research teams, looking to facilitate the largest JIT oncology clinical trial network in the world.